← Leaderboards
Sean Ekins
Genego, Inc.
$25,563,910
Attributed
$28,360,543
Total exposure
30
Grants
28
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.4M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$28,360,543 · 30
By mechanism
R44$11,862,234 · 6
R42$4,221,720 · 3
SB1$3,953,139 · 1
R43$3,076,074 · 9
N44$1,999,195 · 1
R41$1,438,772 · 7
Top collaborators
- Jonathan D Cooper3 shared
- Ester Cerdeira Sabino3 shared
- Jair Lage Siqueira-Neto3 shared
- Daniela Brunner2 shared
- Nathan J Cherrington2 shared
- Robert A Davey2 shared
- Alfredo Garzino-Demo2 shared
- Joel Stephen Freundlich1 shared
Others in their field
Top investigators on “Pharmacologic Substance”
- David Heimbrook · Leidos Biomedical Research, Inc.$127,683,054
- Myron S Cohen · Family Health International$104,232,876
- Wafaa M. El-Sadr · Columbia University Health Sciences$104,068,526
- Garret A Fitzgerald · University Of Pennsylvania$73,814,804
- James Dennis Neaton · Northwestern University$65,107,995
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$53,206,876
Research focus
Pharmacologic SubstancePharmaceutical PreparationsIn VivoCollaborationsToxic EffectDrug DiscoveryIn VitroBasePropertyData SetMachine LearningValidationLeadNovel TherapeuticsDoseComputer SoftwareStructureDatabasesCessation Of LifeDesignCellsAlgorithmsEnzymesPathway Interactions
Grant awards (54)
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease$2,112,893
SB1 · FY2025 · NS · contact PI
Discovery and Development of Oral Small-molecule Direct-acting Antivirals$1,999,195
N44 · FY2025 · AI · contact PI
Machine learning approaches to predict Acetylcholinesterase inhibition and model applications$1,317,335
R44 · FY2025 · ES · contact PI
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease$1,840,246
SB1 · FY2024 · NS · contact PI
Machine learning approaches to predict Acetylcholinesterase inhibition and model applications$727,312
R44 · FY2024 · ES · contact PI
Machine Learning Phenotypic De Novo Drug Design$499,946
R43 · FY2024 · MH
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease$1,499,923
R44 · FY2023 · NS · contact PI
MegaTrans â human transporter machine learning models$864,767
R42 · FY2023 · GM · contact PI
MegaTox for analyzing and visualizing data across different screening systems$855,003
R44 · FY2023 · ES · contact PI
Machine Learning Phenotypic De Novo Drug Design$499,946
R43 · FY2023 · MH
Preclinical development of a Nipah Virus inhibitor$295,096
R43 · FY2023 · AI · contact PI
Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease$1,499,923
R44 · FY2022 · NS · contact PI
MegaTrans â human transporter machine learning models$864,767
R42 · FY2022 · GM · contact PI
MegaTox for analyzing and visualizing data across different screening systems$855,003
R44 · FY2022 · ES · contact PI
Centralized assay datasets for modelling support of small drug discovery organizations$854,677
R44 · FY2022 · GM · contact PI
Machine learning approaches to predict Acetylcholinesterase inhibition$256,385
R43 · FY2022 · ES · contact PI
New therapeutic approaches to identifying molecules for opioid abuse treatment$256,220
R43 · FY2022 · DA · contact PI
Centralized assay datasets for modelling support of small drug discovery organizations$855,127
R44 · FY2021 · GM · contact PI
MegaPredict for predicting natural product uses and their drug interactions$155,686
R43 · FY2020 · AT · contact PI
MegaTox for analyzing and visualizing data across different screening systems$124,915
R43 · FY2020 · ES · contact PI
Centralized assay datasets for modelling support of small drug discovery organizations$692,845
R44 · FY2019 · GM · contact PI
MegaTox for analyzing and visualizing data across different screening systems$224,548
R43 · FY2019 · ES · contact PI
MegaTrans â human transporter machine learning models$210,712
R41 · FY2019 · GM · contact PI
New generation of non-nucleoside RT HIV inhibitors avoiding HIV-associated neurocognitive disorders$196,300
R01 · FY2019 · NS · contact PI
Centralized assay datasets for modelling support of small drug discovery organizations$188,759
R44 · FY2019 · GM · contact PI
Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses$127,300
R43 · FY2019 · NS · contact PI
MegaPredict for predicting natural product uses and their drug interactions$68,862
R43 · FY2019 · AT · contact PI
Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses$54,663
R43 · FY2019 · NS · contact PI
Repurposing pyronaridine as a treatment for Chagas disease$7,630
UH2 · FY2019 · TR · contact PI
Centralized assay datasets for modelling support of small drug discovery organizations$694,172
R44 · FY2018 · GM · contact PI
Repurposing pyronaridine as a treatment for Chagas disease$300,277
UH2 · FY2018 · TR · contact PI
Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses$229,560
R43 · FY2018 · NS · contact PI
Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasA$224,998
R41 · FY2018 · AI · contact PI
New generation of non-nucleoside RT HIV inhibitors avoiding HIV-associated neurocognitive disorders$196,300
R01 · FY2018 · NS · contact PI
Development and validation of therapy for mucopolysaccharidosis III$777,801
R42 · FY2017 · NS · contact PI
Repurposing pyronaridine as a treatment for Chagas disease$313,687
UH2 · FY2017 · TR · contact PI
Repurposing pyronaridine as a treatment for the Ebola virus$312,390
R21 · FY2017 · TR · contact PI
New generation of non-nucleoside RT HIV inhibitors avoiding HIV-associated neurocognitive disorders$194,024
R01 · FY2017 · NS · contact PI
Centralized assay datasets for modelling support of small drug discovery organizations$149,999
R43 · FY2017 · GM · contact PI
Development and validation of therapy for mucopolysaccharidosis III$717,207
R42 · FY2016 · NS · contact PI
Repurposing pyronaridine as a treatment for the Ebola virus$288,801
R21 · FY2016 · TR · contact PI
Engineering stem cells to make mucopolysaccharidosis IIIB$224,469
R41 · FY2016 · NS · contact PI
Optimization of small molecule triazine antituberculars for in vivo efficacy$149,388
R41 · FY2016 · AI · contact PI
Biocomputation across distributed private datasets to enhance drug discovery$379,158
R44 · FY2015 · TR · contact PI
Development and in vitro validation of therapy for mucopolysaccharidosis III$1,500
R41 · FY2015 · NS · contact PI
Biocomputation across distributed private datasets to enhance drug discovery$562,173
R44 · FY2014 · TR · contact PI
Development and in vitro validation of therapy for mucopolysaccharidosis III$223,102
R41 · FY2014 · NS · contact PI
Identification of novel therapeutics for tuberculosis combining cheminformatics,$517,573
R42 · FY2013 · AI · contact PI
Biocomputation across distributed private datasets to enhance drug discovery$462,944
R44 · FY2013 · TR · contact PI
Identification and Validation of Targets of Phenotypic High Throughput Screening$255,221
R41 · FY2013 · AI · contact PI
Identification of novel therapeutics for tuberculosis combining cheminformatics,$479,605
R42 · FY2012 · AI · contact PI
Identification of novel therapeutics for tuberculosis combining cheminformatics,$149,382
R41 · FY2010 · AI · contact PI
Targeted Aggregation Inhibitors for the Treatment of Amyloid Diseases$132,948
R43 · FY2008 · NS · contact PI
In Silico Assesment of Drug Metabolism and Toxicity$417,880
R44 · FY2005 · GM